Press Releases Nevro Corp.

Equities

NVRO

US64157F1030

Market Closed - Nyse Other stock markets 04:00:01 2024-04-26 pm EDT			5-day change	1st Jan Change
11.32 ^USD	-2.58%		-6.21%	-47.40%

Apr. 15	RBC Lowers Price Target on Nevro to $16 From $18, Keeps Sector Perform Rating	MT
Apr. 11	Mizuho Adjusts Price Target on Nevro to $16 From $20, Maintains Neutral Rating	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024	Apr. 17	PR
Non-Opioid Revolution: Beacons of Hope in Opioid Crisis and a $50 Million Spin-Off	Apr. 09	AQ
Nevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral Screw	Feb. 28	PR
Nevro: Q4 Earnings Snapshot	Feb. 21	AQ
Nevro Enters Into Cooperation Agreement With Engaged Capital	Feb. 21	PR
Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results	Feb. 21	PR
Nevro to Report Fourth-Quarter and Full-Year 2023 Financial Results and Host Conference Call on February 21, 2024	Jan. 29	PR
Top 4 Spinal Injury Stocks for 2024 Watchlist (NRX.V, NVRO, SYK, BSX)	Jan. 23	AQ
Top 4 Spinal Injury Stocks for 2024 (NRX.V, NVRO, SYK, BSX)	Jan. 22	AQ
Nevro Announces Positive Coverage Update from Carelon Healthcare for the Treatment of Painful Diabetic Neuropathy	Jan. 19	AQ
Nevro Announces Preliminary Fourth-Quarter and Full-Year 2023 Revenue Results	Jan. 09	PR
Nevro to Present at 42nd Annual J.P. Morgan Healthcare Conference	Jan. 04	PR
Nevro Announces Acquisition of Vyrsa™ Technologies	Nov. 30	PR
Nevro Delivers Long-Term Relief with High-Frequency Spinal Cord Stimulation, 24-Month Data Demonstrates Profound Improvements for Non-Surgical Refractory Back Pain	Nov. 21	AQ
Nevro Delivers Long-Term Relief with High-Frequency Spinal Cord Stimulation: 24-Month Data Demonstrates Profound Improvements for Non-Surgical Refractory Back Pain	Nov. 20	PR
Nevro: Q3 Earnings Snapshot	Nov. 01	AQ
Nevro Reports Third Quarter 2023 Financial Results, Provides Fourth Quarter Guidance and Updates Full-Year 2023 Guidance	Nov. 01	PR
Nevro to Report Third Quarter 2023 Financial Results	23-10-04	PR
New Data Demonstrate the Health Economic Benefits of Nevro's High-Frequency Spinal Cord Stimulation Therapy	23-09-18	PR
Nevro Announces Participation in Upcoming Investor Conferences	23-08-23	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Nevro Corp.

Equities

NVRO

US64157F1030

Press Releases

Filters